Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Research & Development (2018 - 2025)

Entera Bio has reported Research & Development over the past 8 years, most recently at $1.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 43.05% year-over-year to $1.7 million, compared with a TTM value of $6.0 million through Dec 2025, up 33.45%, and an annual FY2025 reading of $6.0 million, up 33.45% over the prior year.
  • Research & Development came in at $1.7 million for Q4 2025, up from $1.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.6 million in Q4 2021 to a low of $735000.0 in Q1 2024.
  • Median Research & Development over the past 5 years was $1.4 million (2022), compared with a mean of $1.4 million.
  • The sharpest move saw Research & Development skyrocketed 128.36% in 2021, then tumbled 49.0% in 2022.
  • Over 5 years, Research & Development stood at $2.6 million in 2021, then tumbled by 49.0% to $1.4 million in 2022, then fell by 25.98% to $1.0 million in 2023, then rose by 20.1% to $1.2 million in 2024, then surged by 43.05% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Research & Development are $1.7 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025).